Vaccines, Pneumococcal
13
0
0
13
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
92%
12 trials in Phase 3/4
77%
10 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (13)
Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia
Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico
Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children